Novartis-GSK-Eli Lilly deal may affect Indian market

Swiss drug major Novartis’ multi-billion-dollar overhaul through deals with two multinational firms -- GlaxoSmithKline and Eli Lilly -- is likely to have an impact on the Indian market, too,......

Biocon inks pact with Mylan

Biocon said on Thursday it has inked an exclusive pact with US-based Mylan to develop and commercialise generic versions of its three insulin products.The Bengaluru-based firm has entered into a......

India, Brazil drag EU to WTO

India and Brazil raised a trade dispute against the European Union before the World Trade Organization on Tuesday over seizure of generic drugs by EU member countries on high seas. In two separate......

'India's patent policy is discouraging innovation'

US-based Eli Lilly - amongst the top 10 global pharmaceutical companies, with annual revenues of $21.8 billion in 2009 - has planned to continue its focus on innovation-driven products, instead of......